• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688580.SS
Share

Nanjing Vishee Medical Technology Co., Ltd Stocks

CN¥ 40.16Last Updated 09.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

CN¥ 603.55M

CN¥ 40.16
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Nanjing Vishee Medical Technology Co., Ltd. is a Chinese firm dedicated to creating and manufacturing a range of medical rehabilitation equipment. Their offerings encompass therapeutic solutions for pelvic floor and postpartum recovery, neurological conditions, and mental health challenges. Additionally, the company provides advanced bio-stimulation feedback instruments and magnetic stimulators. These technologies address diverse areas, including electrical and magnetic stimulation, electrophysiology, and other specialized technical fields. Nanjing Vishee distributes its products to hospitals and various medical and professional end-users primarily through its network of authorized dealers and sales channels. Established in 2001, the company's headquarters are located in Nanjing, China.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 688580.SS is 63.0 and suggests 51.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.10.2026 16:01

What's Important in Small-Cap Stocks: Risks Associated with Webull, Levi's Outlook, and Vaxcyte's Success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

10.10.2026 06:47

Moderna hits four-year high as NYT reports U.S. cancer vaccine effort

10.10.2026 04:58

Palantir shares hit a new high: Barclays followed Goldman in recommending a buy

10.10.2026 04:25

Apple has cut orders for parts for the new iPhones, according to media reports. Was demand lower than expected?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026